Iovance Biotherapeutics, Inc. IOVA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $196.51M+14.5% | $163.08M+41.0% | $158.13M-7.3% | $132.47M-43.7% | $171.67M+27.9% | ||
| $116.94M-37.8% | $133.9M-35.7% | $142.67M-38.8% | $168.71M-8.2% | $188.05M-15.3% | ||
| $5.99M+972% | $5.98M-6.0% | $5.97M-6.1% | $5.94M+7,932% | $559K-91.3% | ||
| $290.91M+27.8% | $280.09M+78.5% | $266.98M+204% | $255.98M+701% | $227.65M+59,030% | ||
| $211.6M+15.3% | $218.77M+61.4% | $218.61M+132% | $205.48M+216% | $183.5M+291% | ||
| $12.93M-18.7% | $11.58M-6.4% | $9.82M+45.6% | $11.55M+13.4% | $15.89M+38.4% | ||
| $466.5M-9.0% | $442.69M-3.1% | $429.09M-13.9% | $422.5M-12.4% | $512.65M+33.0% | ||
| $131.39M+17.8% | $131.11M+20.2% | $126.65M+12.6% | $122.47M+10.4% | $111.58M-0.2% | ||
| $44.38M-12.8% | $45.9M-16.9% | $48.76M+63,328,571,329% | $49.95M+64,868,831,069% | $50.9M-28.8% | ||
| $269.1M-5.7% | $279.32M-1.1% | $285.21M-7.0% | $296.25M+0.3% | $285.36M-3.0% | ||
| $128.81M+0.3% | $130.15M+0.3% | $130.64M+13.8% | $131.19M+30.0% | $128.39M+43.9% | ||
| $8.29M+1,846% | $8.17M+2,113% | $9.27M+3,211% | $10.32M+3,055% | $426K+64.5% | ||
| $925.67M-4.2% | $913.17M+0.3% | $904.95M-8.7% | $907.44M-5.9% | $966.74M+11.1% | ||
| $37.45M+31.5% | $22.16M-19.4% | $31.24M-1.4% | $32M+56.8% | $28.49M+10.9% | ||
| $88.07M+4.0% | $111.16M+35.7% | $87.27M+16.6% | $89.08M+44.2% | $84.71M+82.4% | ||
| $2.9M-65.9% | $4.04M-68.6% | $6.28M-45.6% | $7.07M-38.2% | $8.5M-23.3% | ||
| $129.42M+5.5% | $138.36M+13.1% | $125.79M+6.5% | $129.16M+37.9% | $122.69M+47.4% | ||
| $43.88M-0.8% | $44.4M+0.1% | $45.21M-31.9% | $45.1M-34.9% | $44.22M-38.8% | ||
| $46.78M-11.3% | $48.44M-15.4% | $51.49M-33.9% | $52.17M-35.3% | $52.72M-36.8% | ||
| $74.49M-2.2% | $76.23M-1.9% | $76.88M-22.8% | $79.79M-21.9% | $76.18M-28.5% | ||
| $203.91M+2.5% | $214.59M+7.3% | $202.66M-6.9% | $208.95M+6.7% | $198.88M+4.8% | ||
| —— | —— | —— | —— | —— | ||
| $18K+28.6% | $17K+30.8% | $16K-100.0% | $14K-100.0% | $14K+16.7% | ||
| $3.56B+9.2% | $3.46B+11.7% | $3.39B+10.7% | $3.29B+10.0% | $3.26B+16.3% | ||
| -$2.85B-14.2% | -$2.78B-16.4% | -$2.7B-17.2% | -$2.61B-17.5% | -$2.5B-17.7% | ||
| $12.65M+101% | $16.44M+1,672% | $16.1M-0.9% | $20.86M+3,866% | $6.29M+5,326% | ||
| $721.75M-6.0% | $698.58M-1.7% | $702.29M-9.2% | $698.49M-9.1% | $767.87M+12.9% | ||
| $925.67M-4.2% | $913.17M+0.3% | $904.95M-8.7% | $907.44M-5.9% | $966.74M+11.1% | ||
| $8.29M+1,846% | $8.17M+2,113% | $9.27M+3,211% | $10.32M+3,055% | $426K+64.5% | ||
| $44.38M-12.8% | $45.9M-16.9% | $48.76M-26.9% | $49.95M-27.7% | $50.9M-28.8% | ||
| $269.1M-5.7% | $279.32M-1.1% | $285.21M-7.0% | $296.25M+0.3% | $285.36M-3.0% | ||
| $44.38M-12.8% | $45.9M-16.9% | $48.76M-26.9% | $49.95M-27.7% | $50.9M-28.8% | ||
| $8.29M+1,846% | $8.17M+2,113% | $9.27M+3,211% | $10.32M+3,055% | $426K+64.5% | ||
| $116.94M-37.8% | $133.9M-35.7% | $142.67M-38.8% | $168.71M-8.2% | $188.05M-15.3% | ||
| $44.38M-12.8% | $45.9M-16.9% | $48.76M-26.9% | $49.95M-27.7% | $50.9M-28.8% | ||
| $8.29M+1,846% | $8.17M+2,113% | $9.27M+3,211% | $10.32M+3,055% | $426K+64.5% | ||
| $1M— | $1M— | —— | —— | —— | ||
| $1M— | $1M— | —— | —— | —— | ||
| $88.07M— | $111.16M— | $87.27M— | —— | —— | ||
| $46.78M-11.3% | $48.44M-16.9% | $51.49M-34.8% | $52.17M-36.1% | $52.72M-37.5% | ||
| $18K+28.6% | $17K+30.8% | $16K+23.1% | $14K+16.7% | $14K+16.7% | ||
| $30.61M-4.2% | $31.83M-1.5% | $31.67M-1.7% | $34.7M+8.8% | $31.96M-4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Iovance Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.60 — current assets exceed current liabilities.
- Where does Iovance Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.